APA

Konstantinopoulos P. A., Brady W. E., Farley J., Armstrong A., Uyar D. S. & Gershenson D. M. (20180806). Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). : Gynecologic oncology.

Chicago

Konstantinopoulos Panagiotis A, Brady William E, Farley John, Armstrong Amy, Uyar Denise S and Gershenson David M. 20180806. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). : Gynecologic oncology.

Harvard

Konstantinopoulos P. A., Brady W. E., Farley J., Armstrong A., Uyar D. S. and Gershenson D. M. (20180806). Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). : Gynecologic oncology.

MLA

Konstantinopoulos Panagiotis A, Brady William E, Farley John, Armstrong Amy, Uyar Denise S and Gershenson David M. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). : Gynecologic oncology. 20180806.